
Sign up to save your podcasts
Or


Can cell therapy revolutionize hearing loss treatment? In this follow-up discussion, Brian Culley, CEO of Lineage Cell Therapeutics, shares exciting updates on the ReSonance™ (ANP1) program, a pioneering preclinical study exploring auditory neuron cell transplantation. Culley explains how lab-grown auditory neurons are being delivered to the inner ear to potentially restore damaged auditory pathways—a groundbreaking approach that could even complement existing treatments.
For more information on the ReSonance program, visit the company's website here.
By This Week in Hearing5
11 ratings
Can cell therapy revolutionize hearing loss treatment? In this follow-up discussion, Brian Culley, CEO of Lineage Cell Therapeutics, shares exciting updates on the ReSonance™ (ANP1) program, a pioneering preclinical study exploring auditory neuron cell transplantation. Culley explains how lab-grown auditory neurons are being delivered to the inner ear to potentially restore damaged auditory pathways—a groundbreaking approach that could even complement existing treatments.
For more information on the ReSonance program, visit the company's website here.

7,824 Listeners

2,698 Listeners

113,259 Listeners

56,969 Listeners

1,365 Listeners

20 Listeners

16,410 Listeners

1,469 Listeners